Research progress and prospects of markers for liver cancer stem cells

World Journal of Gastroenterology

Volumn 21, Issue 42, 2015, Pages 12190-12196

  Zhu, Cheng Pei ^a   Wang, An Qiang ^a   Zhang, Hao Hai ^a   Wan, Xue Shuai ^a   Yang, Xiao Bo ^a   Chen, Shu Guang ^a   Zhao, Hai Tao ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

CD91; Epithelial cell adhesion molecule; Hepatocellular carcinoma; Liver cancer stem cells; Surface markers

Indexed keywords

CD133 ANTIGEN; CELL SURFACE MARKER; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; OV6; THY 1 ANTIGEN; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER STEM CELL; CELL DIFFERENTIATION; CELL THERAPY; CLASSIFICATION; DRUG TARGETING; HUMAN; LIVER CANCER; LIVER CANCER STEM CELL; NONHUMAN; REVIEW; SIDE POPULATION CELL; ANIMAL; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SIDE-POPULATION CELLS;

EID: 84947461013     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i42.12190     Document Type: Review

References (60)

1. Lau CK, Yang ZF, Fan ST. Role of stem cells in normal liver and cancer. Anticancer Agents Med Chem 2011; 11: 522-528 [PMID: 21554200 DOI: 10.2174/187152011796011091]
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111 [PMID: 11689955 DOI: 10.1038/35102167]
3. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, Nakauchi H, Iwama A, Taniguchi H. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007; 133: 937-950 [PMID: 17673212 DOI: 10.1053/j.gastro.2007.06.016]
4. Wu XZ, Yu XH. Bone marrow cells: the source of hepatocellular carcinoma? Med Hypotheses 2007; 69: 36-42 [PMID: 17300877 DOI: 10.1016/j.mehy.2006.10.064]
5. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012; 39: 461-472 [PMID: 22846863 DOI: 10.1053/j.seminoncol.2012.05.011]
6. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 2012; 55: 298-306 [PMID: 22030746 DOI: 10.1002/hep.24762]
7. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768 [PMID: 18784658 DOI: 10.1038/nrc2499]
8. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, Hidalgo M, Tsao M, Ailles L, Waddell TK, Maitra A, Neel BG, Matsui W. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010; 7: 279-282 [PMID: 20804964 DOI: 10.1016/j.stem.2010.08.009]
9. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012 [PMID: 9389720]
10. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275: 5512-5520 [PMID: 10681530 DOI: 10.1074/jbc.275.8.5512]
11. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-1153 [PMID: 18644979 DOI: 10.1158/1541-7786.MCR-08-0035]
12. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D, Yoon SK. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012; 315: 129-137 [PMID: 22079466 DOI: 10.1016/j.canlet.2011.10.012]
13. Lan X, Wu YZ, Wang Y, Wu FR, Zang CB, Tang C, Cao S, Li SL. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Int J Mol Med 2013; 31: 315-324 [PMID: 23233126 DOI: 10.3892/ijmm.2012.1208]
14. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824 [PMID: 17097610]
15. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450 [PMID: 17205516 DOI: 10.1002/ijc.22476]
16. Yao J, Zhang T, Ren J, Yu M, Wu G. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep 2009; 22: 781-787 [PMID: 19724856 DOI: 10.3892/or-00000500]
17. Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T, Hayashi N. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 2010; 52: 872-879 [PMID: 20395004 DOI: 10.1016/j.jhep.2009.12.030]
18. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556 [PMID: 17570225 DOI: 10.1053/j.gastro.2007.04.025]
19. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-1218 [PMID: 18479363 DOI: 10.1111/j.1742-1241.2008.01777.x]
20. Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, Schemmer P, Herr I. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2009; 275: 185-193 [PMID: 19026485 DOI: 10.1016/j.canlet.2008.10.015]
21. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cellmatrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006; 20: 1045-1054 [PMID: 16770003]
22. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, Fausto N. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 2006; 103: 9912-9917 [PMID: 16782807 DOI: 10.1073/pnas.0603824103]
23. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166 [PMID: 18242515 DOI: 10.1016/j.ccr.2008.01.013]
24. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT, Fan ST. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-928 [PMID: 18275073 DOI: 10.1002/hep.22082]
25. Sukowati CH, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One 2013; 8: e76830 [PMID: 24116172 DOI: 10.1371/journal.pone.0076830]
26. Michishita M, Ezaki S, Ogihara K, Naya Y, Azakami D, Nakagawa T, Sasaki N, Arai T, Shida T, Takahashi K. Identification of tumorinitiating cells in a canine hepatocellular carcinoma cell line. Res Vet Sci 2014; 96: 315-322 [PMID: 24534130]
27. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484-1497 [PMID: 23174907 DOI: 10.1002/hep.26168]
28. Tanaka M, Okabe M, Suzuki K, Kamiya Y, Tsukahara Y, Saito S, Miyajima A. Mouse hepatoblasts at distinct developmental stages are characterized by expression of EpCAM and DLK1: drastic change of EpCAM expression during liver development. Mech Dev 2009; 126: 665-676 [PMID: 19527784 DOI: 10.1016/j.mod.2009.06.939]
29. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, Kulik M, Sherwood S, Tallheden T, Cheng N, Furth ME, Reid LM. Human hepatic stem cells from fetal and postnatal donors. J Exp Med 2007; 204: 1973-1987 [PMID: 17664288 DOI: 10.1084/jem.20061603]
30. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171 [PMID: 19136966 DOI: 10.1038/ncb1824]
31. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024 [PMID: 19150350 DOI: 10.1053/j.gastro.2008.12.004]
32. Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao W, Shao RG. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 2012; 8: 992-1004 [PMID: 22904667 DOI: 10.7150/ijbs.4454]
33. Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu SJ, Shi RY, Hu B, Zhou J, Fan J. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013; 57: 1458-1468 [PMID: 23175471 DOI: 10.1002/hep.26151]
34. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013; 133: 2165-2171 [PMID: 23616258 DOI: 10.1002/ijc.28230]
35. Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol 2014; 20: 2098-2106 [PMID: 24616575 DOI: 10.3748/wjg.v20.i8.2098]
36. Crosby HA, Hubscher SG, Joplin RE, Kelly DA, Strain AJ. Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology 1998; 28: 980-985 [PMID: 9755234 DOI: 10.1002/hep.510280412]
37. Pusterla T, Nèmeth J, Stein I, Wiechert L, Knigin D, Marhenke S, Longerich T, Kumar V, Arnold B, Vogel A, Bierhaus A, Pikarsky E, Hess J, Angel P. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammationassociated liver carcinogenesis in mice. Hepatology 2013; 58: 363-373 [PMID: 23504974 DOI: 10.1002/hep.26395]
38. Jia SQ, Ren JJ, Dong PD, Meng XK. Probing the hepatic progenitor cell in human hepatocellular carcinoma. Gastroenterol Res Pract 2013; 2013: 145253 [PMID: 23533383 DOI: 10.1155/2013/145253]
39. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, Chen C, Liu SQ, Wu MC, Wang HY. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287-4295 [PMID: 18519688 DOI: 10.1158/0008-5472.CAN-07-6691]
40. Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang L, Yan HX, Fu J, Chen Y, Zhang HL, Tang L, Zheng LY, He YQ, Li YQ, Wu FQ, Zou SS, Li Z, Wu MC, Feng GS, Wang HY. OV6+ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol 2012; 57: 613-620 [PMID: 22612999 DOI: 10.1016/j.jhep.2012.04.024]
41. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-2078 [PMID: 19711346 DOI: 10.1002/ijc.24868]
42. Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res 2012; 22: 259-272 [PMID: 21862973 DOI: 10.1038/cr.2011.139]
43. Thompson SM, Callstrom MR, Butters KA, Sutor SL, Knudsen B, Grande JP, Roberts LR, Woodrum DA. Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol 2014; 37: 1343-1351 [PMID: 24452318]
44. Fernando J, Malfettone A, Cepeda EB, Vilarrasa-Blasi R, Bertran E, Raimondi G, Fabra À, Alvarez-Barrientos A, Fernández-Salguero P, Fernández-Rodríguez CM, Giannelli G, Sancho P, Fabregat I. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int J Cancer 2015; 136: E161-E172 [PMID: 25053293 DOI: 10.1002/ijc.29097]
45. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010; 86: 631-637 [PMID: 20159023]
46. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251 [PMID: 16799977 DOI: 10.1002/hep.21227]
47. Nakayama M, Ogasawara S, Akiba J, Ueda K, Koura K, Todoroki K, Kinoshita H, Yano H. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. J Gastroenterol Hepatol 2014; 29: 1092-1101 [PMID: 24325739 DOI: 10.1111/jgh.12484]
48. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012; 55: 807-820 [PMID: 21994122 DOI: 10.1002/hep.24739]
49. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, Barnard GF, Doki Y, Mori M. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-3339 [PMID: 20697159 DOI: 10.1172/JCI42550]
50. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63 [PMID: 21726833 DOI: 10.1016/j.stem.2011.06.005]
51. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, Ellisman MH, Verma IM. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080-1084 [PMID: 23087000 DOI: 10.1126/science.1226929]
52. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735 [PMID: 22855427 DOI: 10.1126/science.1224676]
53. Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 2011; 26: 1229-1237 [PMID: 21557770 DOI: 10.1111/j.1440-1746.2011.06762.x]
54. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676 [PMID: 16904174 DOI: 10.1016/j.cell.2006.07.024]
55. Scaffidi P, Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011; 13: 1051-1061 [PMID: 21857669 DOI: 10.1038/ncb2308]
56. Vermeulen L, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476 [PMID: 20418870 DOI: 10.1038/ncb2048]
57. Holczbauer A, Factor VM, Andersen JB, Marquardt JU, Kleiner DE, Raggi C, Kitade M, Seo D, Akita H, Durkin ME, Thorgeirsson SS. Modeling pathogenesis of primary liver cancer in lineagespecific mouse cell types. Gastroenterology 2013; 145: 221-231 [PMID: 23523670 DOI: 10.1053/j.gastro.2013.03.013]
58. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP. Liver stem cells and hepatocellular carcinoma. Hepatology 2009; 49: 318-329 [PMID: 19111019 DOI: 10.1002/hep.22704]
59. Ma S. Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res 2013; 319: 126-132 [PMID: 22999864]
60. Zen Y, Fujii T, Yoshikawa S, Takamura H, Tani T, Ohta T, Nakanuma Y. Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 2007; 170: 1750-1762 [PMID: 17456779 DOI: 10.2353/ajpath.2007.060798]